WASHINGTON, DC 20549


                             FORM 8-K


                          CURRENT REPORT
              PURSUANT TO SECTION 13 OR 15(d) OF THE
                 SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): August 30, 1997

         The Interpublic Group of Companies, Inc.                
        (Exact Name of Registrant as Specified in Charter)

  Delaware                    1-6686              13-1024020
(State or other             (Commission         (IRS Employer
 Jurisdiction               File Number)        Identification
of incorporation)                                   Number)

   1271 Avenue of the Americas, New York, New York        10020
  (Address of Principal Executive Offices)             (Zip Code)

Registrant's telephone number, including area code (212) 399-8000

  (Former Name or Former Address, if Changed Since Last Report)


Item 9.   Sales of Equity Securities Pursuant to Regulation S.

     On August 29, 1997, The Interpublic Group of Companies, Inc.
("Interpublic") sold 708,789 shares of its common stock, par
value $.10 (the "Shares"), to ten individuals (the "Purchasers")
in exchange for 21,050,000 Pounds Sterling in value of Ordinary
Shares,  1 Pound Sterling par value, of Complete Medical Group
Limited, a United Kingdom company ("CMG").

     As a result of this, Interpublic has acquired 100% of the
capital stock of CMG.

      No underwriter or placement agent was used in connection
with the sale of the Shares.  

     The transaction was effected in an "offshore transaction"
and in accordance with the "offering restrictions" and "no
directed selling efforts" requirements of Rule 903(c)(2) of
Regulation S under the Securities Act of 1933.


     Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.

                                   THE INTERPUBLIC GROUP OF
                                   COMPANIES, INC.

Date: September 8, 1997                 By:    NICHOLAS J. CAMERA
                                          Vice President,
                                          General Counsel and